Literature DB >> 16887696

Antibiotic resistance among anaerobic Gram-negative bacilli: lessons from a French multicentric survey.

J Behra-Miellet1, L Calvet, F Mory, C Muller, M Chomarat, M C Bézian, S Bland, M E Juvenin, T Fosse, F Goldstein, B Jaulhac, L Dubreuil.   

Abstract

Temporal changes of antibiotic susceptibilities among anaerobes in France are followed in our laboratory since 1992. For Bacteroides strains, resistance increased from 1992 to 1998 for amoxicillin-clavulanic acid, cefotetan and clindamycin. The present study evaluates the situation in 2000 for 434 Gram-negative anaerobic clinical isolates (obtained from 9 large university hospitals) by testing amoxicillin and ticarcillin alone or combined with clavulanic acid, cefoxitin, cefotetan, imipenem, clindamycin and metronidazole (using the NCCLS-approved method for MIC determination. The main genera tested included Bacteroides (359 strains of the fragilis group), Prevotella (40 strains), Fusobacterium (23 strains) and miscellaneous species (8 strains). Resistance rates within the B. fragilis group were: amoxicillin-clavulanic acid 5.6%, ticarcillin 33%, ticarcillin-clavulanic acid 2%, cefoxitin 13%, cefotetan 44%, clindamycin 33%, imipenem 1% and metronidazole <1%, respectively. Only one strain of B. fragilis was resistant to metronidazole (MIC=64 mg/L); due to the presence of the nimA gene on the chromosome. Resistance to imipenem or metronidazole was only found among the B. fragilis species. These two former drugs excepted, B. fragilis was less resistant to antibiotics than the other species. beta-lactamase production was detected for 357/359 strains of the fragilis group, 26/40 stains of Prevotella and 3/23 strains of Fusobacterium. Dynamic changes of antibacterial resistance are occurring within the B. fragilis group: decreased resistance to amoxicillin-clavulanic acid, ticarcillin-clavulanic acid, imipenem while resistance for cefoxitin, cefotetan, clindamycin continues to increase. Regular antibiotic surveys are needed as a source of information to guide the empirical therapy of anaerobic infections.

Entities:  

Year:  2003        PMID: 16887696     DOI: 10.1016/S1075-9964(03)00066-0

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  6 in total

1.  Prognostic factors and impact of antibiotherapy in 117 cases of anaerobic bacteraemia.

Authors:  R Robert; A Deraignac; G Le Moal; S Ragot; G Grollier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-21       Impact factor: 3.267

2.  Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole.

Authors:  M N Austin; R H Beigi; L A Meyn; S L Hillier
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 3.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 4.  Bacteroides: the good, the bad, and the nitty-gritty.

Authors:  Hannah M Wexler
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

5.  Prevotella melaninogenica, a Sentinel Species of Antibiotic Resistance in Cystic Fibrosis Respiratory Niche?

Authors:  Claudie Lamoureux; Charles-Antoine Guilloux; Elise Courteboeuf; Stéphanie Gouriou; Clémence Beauruelle; Geneviève Héry-Arnaud
Journal:  Microorganisms       Date:  2021-06-11

6.  Imipenem Resistance among Gram-Negative and Gram-Positive Bacteria in Hospitalized Patients.

Authors:  A Khorshidi; Ar Sharif
Journal:  Iran J Public Health       Date:  2010-06-30       Impact factor: 1.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.